159 related articles for article (PubMed ID: 14628595)
21. Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate.
Louis SN; Wang L; Chow L; Rezmann LA; Imamura K; MacGregor DP; Casely D; Catt KJ; Frauman AG; Louis WJ
Cancer Detect Prev; 2007; 31(5):391-5. PubMed ID: 18031950
[TBL] [Abstract][Full Text] [Related]
22. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
24. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].
Tao ZH; Mao XL; Wang CH; Chen XD; Yu KY; Weng ZL; Hu YP; Zhang XH; Xie H; Wang OC; Song QT; Li CD; Chen ZG
Zhonghua Nan Ke Xue; 2007 Feb; 13(2):130-3. PubMed ID: 17345768
[TBL] [Abstract][Full Text] [Related]
25. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
[TBL] [Abstract][Full Text] [Related]
26. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
27. MUC1 expression in human prostate cancer cell lines and primary tumors.
O'Connor JC; Julian J; Lim SD; Carson DD
Prostate Cancer Prostatic Dis; 2005; 8(1):36-44. PubMed ID: 15477874
[TBL] [Abstract][Full Text] [Related]
28. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
[TBL] [Abstract][Full Text] [Related]
29. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
30. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
[TBL] [Abstract][Full Text] [Related]
31. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
32. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
33. [Tumor infiltrating dendritic cells in relation to prognosis of lung cancer].
Gong X; Yan Y; Wu J
Zhonghua Zhong Liu Za Zhi; 2000 Mar; 22(2):135-7. PubMed ID: 11776641
[TBL] [Abstract][Full Text] [Related]
34. [Expression of VEGF in prostate cancer and its correlation with ET-1].
Zhou WQ; Yin HL; Zhang ZY; Yi XM; Ge JP; Zhou SG; Cheng W; Wei W; Ma HQ; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):987-92. PubMed ID: 19102498
[TBL] [Abstract][Full Text] [Related]
35. [P53 expression and its clinical significance in prostatic carcinoma].
Jiang T; Jiang H; Song XS; Li XC; Li QL
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical staining of mucin 1 in prostate tissues.
Rabiau N; Dechelotte P; Guy L; Satih S; Bosviel R; Fontana L; Kemeny JL; Boiteux JP; Bignon YJ; Bernard-Gallon D
In Vivo; 2009; 23(2):203-7. PubMed ID: 19414404
[TBL] [Abstract][Full Text] [Related]
37. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
Abdou AG; Aiad HA; Sultan SM
APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
[TBL] [Abstract][Full Text] [Related]
38. MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage.
Kirschenbaum A; Itzkowitz SH; Wang JP; Yao S; Eliashvili M; Levine AC
Mol Urol; 1999; 3(3):163-168. PubMed ID: 10851319
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
Nikoleishvili D; Pertia A; Tsintsadze O; Gogokhia N; Chkhotua A
Georgian Med News; 2007 Feb; (143):34-8. PubMed ID: 17404436
[TBL] [Abstract][Full Text] [Related]
40. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
